Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04695990

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
  • Jun Li Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04695990
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04695990. Randomized; no masking; primary purpose treatment. Start 2021-01-15 (anticipated); primary completion 2022-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Clinical and Mechanism of Wenyang Huoxue Decoction in Treating Heart Failure After Myocardial Infarction
Condition
Heart Failure
Intervention (Drug)
Wenyang Huoxue Decoction
Intervention (Drug)
Wenyang Huoxue placebo
Lead sponsor
Jun Li (class: other)

Record details

Record id
cardio:ct-nct04695990
Content hash
3222c043b8835de40c3ffd6f7e0c514632887d2b3b6a1dd7de755e6b11684b2d